Patrice Chevallier
French Institute of Health and Medical Research
438 Papers
1.6K Citations
Patrice Chevallier is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Transplantation & Medicine. The author has an hindex of 40, co-authored 352 publications. Previous affiliations of Patrice Chevallier include Paris Descartes University & Katholieke Universiteit Leuven.
Chat about Author
Papers
Fludarabine, antithymocyte globulin, and very low-dose busulfan for reduced-intensity conditioning before allogeneic stem cell transplantation in patients with lymphoid malignancies.
Florent Malard,Xavier Cahu,Aline Clavert,Eolia Brissot,Patrice Chevallier,Thierry Guillaume,Jacques Delaunay,Sameh Ayari,Viviane Dubruille,Beatrice Mahe,Thomas Gastinne,Nicolas Blin,Jean-Luc Harousseau,Philippe Moreau,Noel Miplied,Steven Le Gouill,Mohamad Mohty +16 more
TL;DR: Results suggest that reduced-intensity conditioning based on Flu, very low-dose BU, and ATG has the potential to induce long-term remissions in patients with lymphoid malignancies.
18
Towards a Pediatric Approach in Adults with Acute Lymphoblastic Leukemia (ALL): The GRAALL-2003 Study.
Françoise Huguet,Emmanuel Raffoux,Xavier Thomas,Thibaut Leguay,Patrice Chevallier,Martine Escoffre,Oumedaly Reman,Denis Caillot,Norbert Vey,Nicolas Boissel,Mathilde Hunault,Agnès Buzyn,Yves Chalandon,André Delannoy,Jean-Paul Vernant,Véronique Lhéritier,Marie-Christine Béné,Elizabeth Macintyre,Norbert Ifrah,Hervé Dombret +19 more
TL;DR: The GRAALL-2003 study was designed to offer a pediatric approach in adults with Ph-negative ALL until 60 years of age, and demonstrated a large benefit in outcome when adolescents and young adults were treated in a pediatric rather than an adult ALL protocol.
18
Contribution of Revised International Prognostic Scoring System Cytogenetics to Predict Outcome After Allogeneic Stem Cell Transplantation for Myelodysplastic Syndromes: A Study From the French Society of Bone Marrow Transplantation and Cellular Therapy.
Jordan Gauthier,Gandhi Damaj,Carole Langlois,Marie Robin,Mauricette Michallet,Patrice Chevallier,Yves Beguin,Stéphanie Nguyen,Pierre Bories,Didier Blaise,Jérôme Cornillon,Aline Clavert,Mohamad Mohty,Anne Huynh,Anne Thiebaut-Bertrand,Stephane Vigouroux,Alain Duhamel,Ibrahim Yakoub-Agha +17 more
TL;DR: Overall, the C-IPSS-R changed the IPSS cytogenetic risk only in 8% of cases but identified a new risk group, the very poor C-IPSS-R category, with dismal outcome after allogeneic stem cell transplantation.
18
In patients older than 55 years with AML in first CR, should we search for a matched unrelated donor when an old sibling donor is available?
R. Peffault de Latour,M. Labopin,Jonathan Cornelissen,Stephane Vigouroux,Charles Craddock,Didier Blaise,Anne Huyn,Lars Vindeløv,Johan Maertens,Patrice Chevallier,Nathalie Fegueux,Gérard Socié,Gérard Socié,J.Y. Cahn,Eefke Petersen,Harry C. Schouten,Bruno Lioure,Nigel H. Russell,Lucía López Corral,Fabio Ciceri,Arnon Nagler,M. Mohty +21 more
TL;DR: HLA-identical sibling donors aged55 years or more should not be excluded because of age for patients aged 55 years and older with AML in CR1, and 3-year overall survival was 49% with both MSD and MUD.
18
Azacitidine after allo-SCT: the good without the bad?
Mohamad Mohty,Patrice Chevallier +1 more
TL;DR: It is shown that azacitidine after allogeneic stem cell transplantation can increase the number of regulatory T cells (Tregs) while inducing a cytotoxic CD8 + T-cell response, suggesting a potential mechanism for augmenting the graft-versus-leukemia (GVL) effect without increase in graft-Versus host disease (GVHD).
18